• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AnaptysBio (ANAB) Rides A Royalty Driven Narrative, Is The Stock Still A Bargain?

    Simply Wall St·09/06/2026 03:22:43
    Listen to the news

    AnaptysBio (ANAB) is drawing attention after recent share moves, with the stock last closing at US$56.80. Investors are weighing that price against the company’s clinical pipeline and current financial profile.

    Over the past year, AnaptysBio has moved from a relatively quiet stock into one with strong total shareholder return, with a very large 1 year total shareholder return of 289.10% and a 90 day share price return of 10.59%, suggesting momentum has been building recently.

    Scan for other potential breakouts by comparing AnaptysBio with a hand picked set of 19 high quality undiscovered gems that combine strong fundamentals with recent momentum.

    AnaptysBio’s surge has already rewarded early holders, yet the current price still sits well below some valuation markers. Has the stock already reflected most of that optimism, or is there meaningful upside still on the table?

    Most Popular Narrative: 36.9% Undervalued

    The most followed narrative on AnaptysBio pegs fair value at $90 per share versus the recent $56.80 close. This implies a wide gap that this narrative tries to explain through royalties, leverage and a legal overhang.

    ANAB has a scaling and rising royalty stream, one up and coming new royalty, a loan that dies in 2027 which will result in a doubling of revenue, and a lawsuit that could soon double the value of the stock.

    Read the complete narrative. Read the complete narrative.

    Want to see how this royalty heavy story gets to that valuation for AnaptysBio? The narrative focuses on accelerating cash flows, expanding margins and a sharp shift in profitability. The fair value depends on how those moving parts line up over the next few years.

    Result: Fair Value of $90 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this AnaptysBio narrative could be knocked off course if the litigation outcome is less favorable than expected or if royalty inflows underperform current assumptions.

    Find out about the key risks to this AnaptysBio narrative.

    Another View on AnaptysBio’s Valuation

    While the user narrative argues AnaptysBio is 36.9% undervalued based on its own fair value estimate, the SWS DCF model is far more optimistic. It values future cash flows at $527.53 per share versus the recent $56.80 price, which also flags the stock as undervalued. The gap between those two fair values raises a clear question: Which set of assumptions do you trust more?

    If you want to see exactly how that cash flow based figure is built, take a closer look at how the SWS DCF model works for AnaptysBio. Look into how the SWS DCF model arrives at its fair value.

    ANAB Discounted Cash Flow as at Sep 2026
    ANAB Discounted Cash Flow as at Sep 2026

    Next Steps

    Given the mix of optimism and unanswered questions around AnaptysBio, it makes sense to review the data yourself and move quickly while sentiment is forming. To see what investors are optimistic about in the company’s profile, check the 2 key rewards.

    Looking for more investment ideas beyond AnaptysBio?

    If you stop with AnaptysBio, you might miss other strong setups. Use the Simply Wall Street Screener to spot fresh ideas before the crowd catches on.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.